Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Staber, PB; Holub, R; Linkesch, W; Schmidt, H; Neumeister, P.
Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.
BONE MARROW TRANSPLANT. 2005; 35(9): 889-893.
Doi: 10.1038/sj.bmt.1704927
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Neumeister Peter
- Staber Philipp
- Co-authors Med Uni Graz
- Linkesch Werner
- Schmidt Helmut
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Infectious complications are frequent events in patients undergoing high-dose cytotoxic chemotherapy with subsequent autologous peripheral blood stem cell transplantation (PBSCT). To evaluate whether a single subcutaneous injection of pegfilgrastim (6 mg) is as safe and effective as daily filgrastim (5 mug/kg/day), 60 consecutive autologous stem cell transplantations performed for various haematological malignancies have been analysed. In total, 24 patients undergoing 30 consecutive PBSCT received a single subcutaneous injection of 6 mg pegfilgrastim on day 5 after transplantation and were compared retrospectively with 30 patients receiving 5 mug/kg/day of filgrastim starting from day 7 post transplantation. The mean duration of grade 4 neutropenia in the pegfilgrastim and filgrastim groups was 8.3 and 9.5 days, respectively (P=0.047). The results of the two groups were not significantly different for incidence of febrile neutropenia and toxicity profile. However, duration of febrile neutropenia (1.6 vs 3.0 days) and total days of fever (1.73 vs 4.1) were different (P=0.017 and 0.003, respectively), favouring the pegfilgrastim arm. Consequently, a higher incidence of transplants with documented infectious complications associated with the filgrastim group could be observed (56 vs 26%) (P=0.02). A single injection of pegfilgrastim administered at day 5 post transplant shows comparable safety and efficacy profiles to daily injections of filgrastim.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Female -
- Filgrastim - administration and dosage
- Hematologic Neoplasms - complications Hematologic Neoplasms - therapy
- Humans -
- Injections, Subcutaneous -
- Lymphoproliferative Disorders - complications Lymphoproliferative Disorders - therapy
- Male -
- Middle Aged -
- Neutropenia - drug therapy Neutropenia - etiology
- Peripheral Blood Stem Cell Transplantation -
- Transplantation, Autologous -
- Find related publications in this database (Keywords)
- pegfilgrastim
- filgrastim
- autologous peripheral blood stem cell transplantation
- PBSCT